Display options
Cite
Zaunders J, van Bockel D. Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease. Front Immunol. 2013;4:95doi: 10.3389/fimmu.2013.00095.
Zaunders, J., & van Bockel, D. (2013). Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease. Frontiers in immunology, 495. https://doi.org/10.3389/fimmu.2013.00095
Zaunders, John, and van Bockel, David. "Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease." Frontiers in immunology vol. 4 (2013): 95. doi: https://doi.org/10.3389/fimmu.2013.00095
Zaunders J, van Bockel D. Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease. Front Immunol. 2013 Apr 24;4:95. doi: 10.3389/fimmu.2013.00095. eCollection 2013. PMID: 23630526; PMCID: PMC3633949.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2013 Apr 24;4:95. doi: 10.3389/fimmu.2013.00095. eCollection 2013.

Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease.

Frontiers in immunology

John Zaunders, David van Bockel

Affiliations

  1. Centre for Applied Medical Research, St Vincent's Hospital Darlinghurst, NSW, Australia.

PMID: 23630526 PMCID: PMC3633949 DOI: 10.3389/fimmu.2013.00095

Abstract

Long-term non-progressors (LTNP) were identified after 10-15 years of the epidemic, and have been the subject of intense investigation ever since. In a small minority of cases, infection with nef/3'LTR deleted attenuated viral strains allowed control over viral replication. A common feature of LTNP is the readily detected proliferation of CD4 T-cells in vitro, in response to p24. In some cases, the responding CD4 T-cells have cytotoxic effector function and may target conserved p24 epitopes, similar to the CD8 T-cells described below. LTNP may also carry much lower HIV DNA burden in key CD4 subsets, presumably resulting from lower viral replication during primary infection. Some studies, but not others, suggest that LTNP have CD4 T-cells that are relatively resistant to HIV infection in vitro. One possible mechanism may involve up-regulation of the cell cycle regulator p21/waf in CD4 T-cells from LTNP. Delayed progression in Caucasian LTNP is also partly associated with heterozygosity of the Δ32 CCR5 allele, probably through decreased expression of CCR5 co-receptor on CD4 T-cells. However, in approximately half of Caucasian LTNP, two host genotypes, namely HLA-B57 and HLA-B27, are associated with viral control. Immunodominant CD8 T-cells from these individuals target epitopes in p24 that are highly conserved, and escape mutations have significant fitness costs to the virus. Furthermore, recent studies have suggested that these CD8 T-cells from LTNP, but not from HLA-B27 or HLA-B57 progressors, can cross-react with intermediate escape mutations, preventing full escape via compensatory mutations. Humoral immunity appears to play little part in LTNP subjects, since broadly neutralizing antibodies are rare, even amongst slow progressors. Recent genome-wide comparisons between LTNP and progressors have confirmed the HLA-B57, HLA-B27, and delta32 CCR5 allelic associations, plus indicated a role for HLA-C/KIR interactions, but have not revealed any new genotypes so far. Nevertheless, it is hoped that studying the mechanisms of intracellular restriction factors, such as the recently identified SAMHD1, will lead to a better understanding of non-progression.

Keywords: HIV-1; cell-mediated immunity; cytotoxic T lymphocytes; elite controllers; long-term non-progressors

References

  1. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73 - PubMed
  2. Curr Opin HIV AIDS. 2011 May;6(3):151-6 - PubMed
  3. AIDS. 1991 Jan;5(1):1-14 - PubMed
  4. J Immunol. 2006 May 15;176(10):6130-46 - PubMed
  5. Blood. 2012 May 17;119(20):4645-55 - PubMed
  6. J Intern Med. 2009 Jan;265(1):29-42 - PubMed
  7. AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1691-8 - PubMed
  8. Nat Genet. 2002 Aug;31(4):429-34 - PubMed
  9. Curr Drug Targets. 2006 Dec;7(12):1571-82 - PubMed
  10. Sci Transl Med. 2012 Feb 29;4(123):123ra25 - PubMed
  11. Front Microbiol. 2012 Mar 15;3:97 - PubMed
  12. Nature. 2000 Sep 28;407(6803):523-6 - PubMed
  13. AIDS. 2005 Nov 18;19(17):2001-7 - PubMed
  14. J Virol. 2000 May;74(9):4361-76 - PubMed
  15. Nat Med. 2010 Apr;16(4):452-9 - PubMed
  16. Lancet. 1999 Nov 20;354(9192):1782-5 - PubMed
  17. Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):E689-98 - PubMed
  18. Retrovirology. 2012 Nov 06;9:91 - PubMed
  19. J Infect Dis. 2008 Jan 1;197(1):126-33 - PubMed
  20. Blood. 2004 Mar 15;103(6):2238-47 - PubMed
  21. Cell. 1990 Apr 20;61(2):213-22 - PubMed
  22. Curr Opin Immunol. 1996 Aug;8(4):472-7 - PubMed
  23. J Infect Dis. 1998 Dec;178(6):1812-5 - PubMed
  24. AIDS Res Hum Retroviruses. 1999 Nov 20;15(17):1519-27 - PubMed
  25. J Virol. 2010 Jun;84(11):5540-9 - PubMed
  26. J Virol. 2006 Oct;80(20):10151-61 - PubMed
  27. J Infect Dis. 2008 Feb 15;197(4):563-71 - PubMed
  28. J Infect Dis. 2005 Jul 1;192(1):46-55 - PubMed
  29. AIDS. 2007 May 11;21(8):1043-5 - PubMed
  30. AIDS. 1997 Dec;11(15):1833-8 - PubMed
  31. J Virol. 2012 Apr;86(7):4014-8 - PubMed
  32. J Virol. 2012 Jan;86(1):277-83 - PubMed
  33. J Immunol. 2010 May 1;184(9):4926-35 - PubMed
  34. Ann Intern Med. 1997 Jun 15;126(12):946-54 - PubMed
  35. AIDS. 2010 Jul 31;24(12):1917-22 - PubMed
  36. Nature. 2002 May 2;417(6884):95-8 - PubMed
  37. Ann Intern Med. 2001 Nov 6;135(9):782-95 - PubMed
  38. Clin Infect Dis. 2012 May;54(10):1495-503 - PubMed
  39. Nat Med. 1996 Nov;2(11):1240-3 - PubMed
  40. J Virol. 2008 Sep;82(17):8422-30 - PubMed
  41. PLoS One. 2008;3(12):e3907 - PubMed
  42. J Infect Dis. 1991 May;163(5):959-65 - PubMed
  43. J Immunol. 2002 Jun 1;168(11):5954-8 - PubMed
  44. J Infect Dis. 2001 Mar 1;183(5):736-43 - PubMed
  45. Trends Immunol. 2003 Dec;24(12):628-32 - PubMed
  46. J Infect Dis. 1999 Jul;180(1):68-75 - PubMed
  47. Science. 1995 Nov 10;270(5238):988-91 - PubMed
  48. PLoS Pathog. 2011 Feb;7(2):e1001300 - PubMed
  49. Immunol Today. 1998 Sep;19(9):395-404 - PubMed
  50. J Virol. 2010 Aug;84(15):7581-91 - PubMed
  51. Annu Rev Med. 2003;54:535-51 - PubMed
  52. Annu Rev Immunol. 2011;29:621-63 - PubMed
  53. Virology. 2002 Dec 20;304(2):246-64 - PubMed
  54. J Biol Chem. 1997 Dec 5;272(49):30603-6 - PubMed
  55. J Virol. 2004 Aug;78(16):8844-51 - PubMed
  56. J Virol. 2007 Dec;81(24):13904-15 - PubMed
  57. Retrovirology. 2008 Sep 22;5:84 - PubMed
  58. J Infect Dis. 1994 May;169(5):968-74 - PubMed
  59. AIDS Res Hum Retroviruses. 2012 Dec;28(12):1565-73 - PubMed
  60. J Acquir Immune Defic Syndr. 2006 Jun;42(2):192-202 - PubMed
  61. Proc Natl Acad Sci U S A. 2005 May 17;102(20):7239-44 - PubMed
  62. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14 - PubMed
  63. Immunity. 1999 Jun;10(6):661-71 - PubMed
  64. Nature. 1998 Jan 22;391(6665):397-401 - PubMed
  65. AIDS. 2002 May 3;16(7):961-72 - PubMed
  66. Science. 1996 Sep 27;273(5283):1856-62 - PubMed
  67. Annu Rev Immunol. 1999;17:625-56 - PubMed
  68. Retrovirology. 2013 Jan 07;10:1 - PubMed
  69. J Virol. 1997 Apr;71(4):3120-8 - PubMed
  70. Blood. 1998 Nov 1;92(9):3105-14 - PubMed
  71. Nat Med. 2007 Jan;13(1):46-53 - PubMed
  72. J Virol. 2007 Nov;81(22):12382-93 - PubMed
  73. J Infect Dis. 1999 Aug;180(2):320-9 - PubMed
  74. J Exp Med. 1998 Dec 21;188(12):2199-204 - PubMed
  75. J Immunol. 2012 Mar 1;188(5):2198-206 - PubMed
  76. Clin Dev Immunol. 2012;2012:153863 - PubMed
  77. J Virol. 2011 Mar;85(5):2316-24 - PubMed
  78. Nat Rev Immunol. 2010 Jan;10(1):11-23 - PubMed
  79. Nat Med. 2010 Oct;16(10):1147-51 - PubMed
  80. N Engl J Med. 2009 Oct 15;361(16):1548-59 - PubMed
  81. J Immunol. 2011 Jan 1;186(1):479-88 - PubMed
  82. Eur J Immunol. 2013 Feb;43(2):510-20 - PubMed
  83. J Clin Invest. 2012 Sep;122(9):3281-94 - PubMed
  84. Nature. 2010 May 20;465(7296):350-4 - PubMed
  85. J Virol. 2004 May;78(9):4463-77 - PubMed
  86. N Engl J Med. 1991 Apr 4;324(14):954-60 - PubMed
  87. J Virol. 2009 Sep;83(17):8616-27 - PubMed
  88. Science. 2010 Dec 10;330(6010):1551-7 - PubMed
  89. J Exp Med. 2007 Nov 26;204(12):2813-24 - PubMed
  90. Nat Med. 2009 Aug;15(8):893-900 - PubMed
  91. PLoS Pathog. 2009 Apr;5(4):e1000377 - PubMed
  92. J Clin Invest. 1989 Dec;84(6):1892-9 - PubMed
  93. J Infect Dis. 2007 Jun 15;195(12):1762-4 - PubMed
  94. J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):140-47 - PubMed
  95. Nature. 2006 Sep 21;443(7109):350-4 - PubMed
  96. Nat Immunol. 2012 Jun 10;13(7):691-700 - PubMed
  97. Blood. 2009 Jul 9;114(2):346-56 - PubMed
  98. J Exp Med. 2009 Jun 8;206(6):1253-72 - PubMed
  99. J Virol. 2011 Jan;85(2):979-86 - PubMed
  100. Blood. 2011 Jul 28;118(4):955-64 - PubMed
  101. Clin Infect Dis. 2005 Oct 1;41(7):1053-6 - PubMed
  102. J Immunol. 2010 Jul 1;185(1):498-506 - PubMed
  103. J Infect Dis. 2011 Mar 15;203(6):803-9 - PubMed
  104. PLoS Pathog. 2012;8(3):e1002529 - PubMed
  105. J Virol. 2013 Apr;87(7):3760-73 - PubMed
  106. J Virol. 2006 Oct;80(20):10162-72 - PubMed
  107. J Exp Med. 2007 Nov 26;204(12):3027-36 - PubMed
  108. J Exp Med. 2012 Jul 30;209(8):1391-5 - PubMed
  109. J Infect Dis. 2005 May 1;191(9):1410-8 - PubMed
  110. Top HIV Med. 2007 Aug-Sep;15(4):134-6 - PubMed
  111. J Clin Invest. 1988 Dec;82(6):1908-14 - PubMed
  112. Blood. 2005 Sep 1;106(5):1660-7 - PubMed
  113. Science. 2007 Aug 17;317(5840):944-7 - PubMed
  114. Ann Intern Med. 1995 Apr 15;122(8):573-9 - PubMed
  115. Nat Immunol. 2002 Nov;3(11):1061-8 - PubMed
  116. J Virol. 2004 Jan;78(2):630-41 - PubMed
  117. PLoS Pathog. 2013 Mar;9(3):e1003211 - PubMed
  118. AIDS. 2010 Nov 13;24(17):2619-28 - PubMed
  119. Eur J Immunol. 1997 Dec;27(12):3223-7 - PubMed
  120. Nat Rev Microbiol. 2007 Feb;5(2):95-106 - PubMed
  121. J Exp Med. 2006 Dec 25;203(13):2865-77 - PubMed
  122. AIDS. 2003 Jan 24;17(2):264-7 - PubMed
  123. Semin Immunol. 2008 Jun;20(3):181-6 - PubMed
  124. Clin Infect Dis. 2009 Sep 15;49(6):982-6 - PubMed
  125. Nature. 1994 Jun 2;369(6479):403-7 - PubMed
  126. AIDS. 2004 Mar 26;18(5):749-55 - PubMed
  127. J Clin Invest. 2011 Apr;121(4):1549-60 - PubMed
  128. Nature. 2011 May 25;474(7353):654-7 - PubMed
  129. Science. 1997 Nov 21;278(5342):1447-50 - PubMed
  130. Retrovirology. 2008 Dec 11;5:112 - PubMed
  131. J Immunol. 2012 Apr 1;188(7):3247-56 - PubMed
  132. Eur J Immunol. 2001 Dec;31(12):3782-8 - PubMed
  133. J Exp Med. 2004 Sep 20;200(6):701-12 - PubMed
  134. Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16233-8 - PubMed
  135. Nat Immunol. 2012 Feb 12;13(3):223-228 - PubMed
  136. Cell. 1998 May 29;93(5):673-6 - PubMed
  137. Nature. 2010 Mar 11;464(7286):217-23 - PubMed
  138. Nat Med. 1997 Feb;3(2):212-7 - PubMed
  139. J Clin Invest. 2001 Feb;107(4):505-17 - PubMed
  140. Nat Rev Immunol. 2004 Aug;4(8):630-40 - PubMed
  141. Virology. 2010 Sep 15;405(1):81-92 - PubMed
  142. J Virol. 2011 Jan;85(2):733-41 - PubMed
  143. N Engl J Med. 1995 Jan 26;332(4):209-16 - PubMed
  144. J Immunol. 1999 Oct 15;163(8):4597-603 - PubMed
  145. Nat Med. 2002 May;8(5):493-9 - PubMed
  146. AIDS. 2011 Nov 13;25(17):2069-78 - PubMed
  147. J Exp Med. 2007 Oct 1;204(10):2473-85 - PubMed
  148. Nature. 2000 Sep 21;407(6802):386-90 - PubMed
  149. Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81 - PubMed
  150. Nature. 2001 Jul 19;412(6844):334-8 - PubMed
  151. J Immunol. 2007 Mar 1;178(5):2746-54 - PubMed
  152. J Exp Med. 2001 Feb 5;193(3):375-86 - PubMed
  153. J Virol. 2012 Sep;86(18):9802-16 - PubMed
  154. Blood. 2006 Jun 15;107(12):4781-9 - PubMed
  155. J Infect Dis. 2010 Jan 15;201(2):272-84 - PubMed
  156. J Virol. 2010 Apr;84(7):3644-53 - PubMed
  157. Annu Rev Microbiol. 1996;50:825-54 - PubMed
  158. Nature. 2011 Jun 29;474(7353):658-61 - PubMed
  159. Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9791-6 - PubMed
  160. Nature. 2011 Nov 06;480(7377):379-82 - PubMed
  161. Science. 2010 Aug 13;329(5993):811-7 - PubMed
  162. PLoS Pathog. 2010 Feb 26;6(2):e1000780 - PubMed
  163. Retrovirology. 2007 Sep 23;4:66 - PubMed
  164. J Clin Invest. 2012 Sep;122(9):3271-80 - PubMed
  165. J Immunol. 2008 Oct 1;181(7):5137-46 - PubMed
  166. PLoS Pathog. 2008 Feb 8;4(2):e18 - PubMed
  167. J Immunol. 2011 Jan 1;186(1):359-71 - PubMed
  168. Annu Rev Immunol. 2004;22:745-63 - PubMed
  169. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13878-83 - PubMed
  170. Nature. 2011 Apr 28;472(7344):495-8 - PubMed
  171. Blood. 2009 Jun 18;113(25):6351-60 - PubMed
  172. J Virol. 2007 Mar;81(5):2508-18 - PubMed
  173. Nature. 2011 Sep 22;477(7365):466-70 - PubMed
  174. AIDS. 1995 Jun;9(6):561-6 - PubMed
  175. J Virol. 1994 Jul;68(7):4650-5 - PubMed
  176. J Exp Med. 2001 Jan 15;193(2):181-94 - PubMed
  177. PLoS One. 2012;7(2):e29844 - PubMed
  178. J Infect Dis. 2009 Dec 1;200(11):1714-23 - PubMed
  179. Lancet. 1985 Mar 9;1(8428):537-40 - PubMed
  180. J Infect Dis. 1998 Mar;177(3):551-6 - PubMed
  181. Nat Immunol. 2007 Nov;8(11):1246-54 - PubMed
  182. Lancet. 1992 Oct 10;340(8824):863-7 - PubMed
  183. Clin Infect Dis. 2010 Jul 15;51(2):233-8 - PubMed
  184. AIDS. 2003 Dec 5;17(18):2581-91 - PubMed
  185. Science. 1986 Dec 19;234(4783):1563-6 - PubMed
  186. J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):127-31 - PubMed
  187. Hum Immunol. 2004 May;65(5):486-92 - PubMed

Publication Types